Key Points
- Director Leon Recanati bought 460,000 Evogene shares at an average price of $0.64, investing $294,400 and increasing his direct ownership by 52.04% to 1.34 million shares.
- Evogene reported a quarterly loss of $0.60 per share, significantly missing the $0.27 consensus estimate, while revenue of $0.33 million was slightly below expectations.
- The stock opened at $0.65, with a market capitalization of approximately $5.68 million; the sole analyst rating remains Sell, although institutional investors own 10.4% of the company.
Evogene Ltd. (NASDAQ:EVGN - Get Free Report) Director Leon Recanati purchased 460,000 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $294,400.00. Following the completion of the transaction, the director directly owned 1,343,886 shares in the company, valued at approximately $860,087.04. This represents a 52.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Evogene Price Performance
Shares of NASDAQ EVGN opened at $0.65 on Friday. The stock has a market capitalization of $5.68 million, a price-to-earnings ratio of -0.47 and a beta of 1.40. The business has a 50-day moving average of $0.53 and a 200-day moving average of $0.73. Evogene Ltd. has a fifty-two week low of $0.37 and a fifty-two week high of $1.50.
Evogene (NASDAQ:EVGN - Get Free Report) last released its earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The company had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.35 million.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Evogene in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of "Sell".
Read Our Latest Analysis on Evogene
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC grew its position in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 12,387 shares during the period. XTX Topco Ltd bought a new stake in shares of Evogene in the 4th quarter valued at about $25,000. Finally, Citadel Advisors LLC raised its holdings in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 36,206 shares during the period. Institutional investors own 10.40% of the company's stock.
About Evogene
(
Get Free Report)
Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene's platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.
In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
